Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy.
Read the full article on WikipediaLocally advanced or metastatic breast cancer Clinical criteria: Treatment Phase: Initial treatment Patient must be untreated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitor therapy; OR Patient must have developed an intolerance to another CDK4/6 inhibitor therapy (other than this drug) of a severity necessitating permanent treatment withdrawal, AND The condition must be hormone receptor positive, AND The condition must be human epidermal growth factor receptor 2 (HER2) negative, AND The condition must be inoperable, AND Patient must have a World Health Organisation (WHO) Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less, AND The treatment must be in combination, where the patient has never been treated with endocrine therapy for advanced/metastatic disease, with a non-steroidal aromatase inhibitor; OR The treatment must be in combination, where the patient has recurrence/progressive disease despite being treated with endocrine therapy for advanced/metastatic disease, with fulvestrant only, AND The treatment must not be in combination with another cyclin-dependent kinase 4/6 (CDK4/6) inhibitor therapy. Treatment criteria: Must be treated by a medical practitioner. Population criteria: Patient must not be premenopausal. PBS-subsidised treatment with CDK 4/6 inhibitors is restricted to one line of therapy at any disease staging for breast cancer (i.e. if therapy has been prescribed for early disease, subsidy under locally advanced or metastatic disease is no longer available).
“It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.”
“29 (±5) hours”
Working under the parallel aged-care framework? Aged-care equivalent →